[IN-DEPTH ANALYSIS] ResMed: The Leader in Sleep Health, Powering Future Investment Growth
The current P/E ratio is 21x, lower than the five-year average of 32x. The target price for fiscal year 2026 is expected to be $295 (with a P/E ratio of 27x).
TradingKeyJun 4, 2025